COPENHAGEN () -Wegovy-maker Novo Nordisk lowered its full-year profit forecast on Wednesday in an early blow to the Danish drugmaker's new CEO amid a deep restructuring drive to claw back lost ground in a fierce obesity drug market battle.

Novo Nordisk CEO Maziar Mike Doustdar discusses demand for the Danish firm's weight-loss drug Wegovy and diabetes medication Ozempic. He also comments on the $10 billion bid for obesity startup Metsera and the prospects for a deal with the Trump administration on US pricing.

Shares of Hims & Hers Health ($HIMS) rallied on Tuesday after management said it’s in discussions with Novo Nordisk ($NVO) to offer oral Wegovy

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes and obesity medicines Ozempic, Wegovy and Rybelsus, which will become effective in January 2027.

There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company boasts a strong pipeline of products in development, solid revenue growth and promising growth prospects in diabetes treatment and weight management. In the first half of the year, total revenue rose 16% year over year.

Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo Nordisk A/S (NYSE:NVO)’s top investor, the non-profit Novo Nordisk Foundation,

Third-quarter results will be the first for Mike Doustdar who was tasked in August with turning around the Danish company's fortunes.